South Korean biotechnology company IntoCell has announced a memorandum of understanding (MoU) with US-based contract development and manufacturing organisation (CDMO) Xcellon Biologics, aimed at enhancing the development and production of antibody–drug conjugates (ADCs).
The collaboration is aimed at merging the chemistry platform of IntoCell with the CDMO manufacturing resources of Xcellon in the US, aiming to speed up accessibility to ADC technologies.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataXcellon will incorporate IntoCell’s OHPAS drug-linker system into its range of ADC development suite. OHPAS includes Duocarmycin and Nexatecan-based payloads.
This enables Xcellon to deliver bioconjugation and ADC manufacturing services to pharma and biotech companies that choose to use IntoCell’s technology in their research initiatives.
IntoCell CEO Tae Kyo Park stated: “We are pleased to collaborate with Xcellon Biologics, a leading CDMO company. We will endeavour to ensure the mutual success of both companies by combining respective areas of expertise.
“By integrating IntoCell’s proprietary OHPAS linker and payload platforms with Xcellon’s bioconjugation and manufacturing expertise, we aim to provide global innovators with the tools and support necessary to bring differentiated ADC therapies to patients faster.”
The partnership is aligned with the companies’ shared goal of making ADC research and production capabilities widely available.
Xcellon Biologics chief operating officer and co-founder Yuk Chiu stated: “This collaboration enhances Xcellon’s ADC toolbox and enables our clients to explore a wider range of payload-linker combinations efficiently.
“By integrating IntoCell’s technologies into our platform, we can accelerate timelines and expand innovation opportunities for next-generation ADC programmes.”
IntoCell focuses on creating linker and payload solutions for next-generation ADCs.
Xcellon Biologics, which operates as Linden Lake Labs’ wholly owned subsidiary, specialises in complex biologics such as T-cell engagers, bioconjugates, bispecific antibodies and ADCs.
The company supports projects from early-stage discovery through to investigational new drug application submission with its scaleable development model.
ADC content on Pharmaceutical Technology (Or Clinical Trials Arena) is supported by Syngene. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
